igg4.org

Soutien et sources

Nous renvoyons vers des organisations et des sources publiées de confiance. igg4.org est indépendant, sans financement ni parrainage de l'industrie. Une mention ici est une reconnaissance, pas un filtre.

Littérature médicale principale

Les sources publiées sur lesquelles repose ce site. Lorsque c'est possible, nous renvoyons vers une version consultable en intégralité, sinon vers la notice de publication. Ceci est une information et ne remplace pas votre spécialiste.

  1. 1.Della-Torre E, Talarico R, Ballarin J, et al. Identification of red flags for IgG4-related disease: an international European Reference Network for Rare Connective Tissue Diseases framework. Lancet Rheumatol 2025;7(1):e64-e71

    Lire la source

  2. 2.Wallace ZS, Naden RP, Chari S, et al. The 2019 ACR/EULAR classification criteria for IgG4-related disease. Arthritis Rheumatol 2020;72(1):7-19

    Lire la source

  3. 3.Wallace ZS, Katz G, Hernandez-Barco YG, Baker MC. Current and future advances in practice: IgG4-related disease. Rheumatol Adv Pract 2024;8(2):rkae020

    Lire la source

  4. 4.Iaccarino L, Talarico R, Scire CA, et al. IgG4-related diseases: state of the art on clinical practice guidelines. RMD Open 2019;4(Suppl 1):e000787

    Lire la source

  5. 5.Sina S, Bonisoli GL, et al. Clinicopathological pearls and diagnostic pitfalls in IgG4-related disease. Diagnostics 2025;15(18):2299

    Lire la source

  6. 6.Maritati F, Peyronel F, Vaglio A. IgG4-related disease: a clinical perspective. Rheumatology 2020;59(Suppl 3):iii123-iii131

    Lire la source

  7. 7.Khosroshahi A, Wallace ZS, Crowe JL, et al. International consensus guidance statement on the management and treatment of IgG4-related disease. Arthritis Rheumatol 2015;67(7):1688-1699

    Lire la source

  8. 8.Stone JH, et al. Inebilizumab for treatment of IgG4-related disease. New England Journal of Medicine, 2025.

    Lire la source

  9. 9.Cagnotto G, Backlund RT, Bengtsson A, Bruschettini M. Immunosuppressants for IgG4-related disease (protocol). Cochrane Database Syst Rev 2025;(8):CD016094

    Lire la source

  10. 10.Cuéllar MC, et al. Enfermedad relacionada a IgG4. Serie clínica de pacientes chilenos. Rev Med Chile 2022;150:705-710.

    Lire la source

  11. 11.Lanzillotta M, Campochiaro C, Mancuso G, et al. Clinical phenotypes of IgG4-related disease reflect different prognostic outcomes. Rheumatology (Oxford) 2020;59:2435-2442.

    Lire la source

  12. 12.Okazaki K (ed.). IgG4-Related Disease. Current Topics in Microbiology and Immunology, vol. 401. Springer International Publishing, 2017.

    Lire la source

  13. 13.Orozco Gálvez O. Enfermedad relacionada con la IgG4: creación de un algoritmo diagnóstico y terapéutico europeo y nuevas técnicas de medicina nuclear. Doctoral thesis, Universitat Autònoma de Barcelona, 2024.

    Lire la source

  14. 14.Bateman AC, Culver EL. Challenges and pitfalls in the diagnosis of IgG4-related disease. Semin Diagn Pathol 2024;41(2):45-53

    Lire la source

  15. 15.Reisch M, Spindelböck WJ, Hodl I, Pietsch D, Rainer F, Kickinger D, Sutic A, Thiel J, Stradner M. Azathioprine as maintenance therapy for IgG4-related diseases. Rheumatology International 2026;46(3):47.

    Lire la source

  16. 16.Hammitzsch A, Ferraro N, Bachmann Q, Heemann U, Moog P. Long-term treatment patterns and outcomes in IgG4-related disease: a retrospective single-center cohort study focusing on rituximab. Rheumatology International 2026;46:33.

    Lire la source

  17. 17.Taranto S, Bernardo L, Mauro A, Perrone A, Tamborino A, Giani T. IgG4-Related Disease in Childhood: Clinical Presentation, Management, and Diagnostic Challenges. Children (Basel) 2025;12(7):888.

    Lire la source

  18. 18.González-García A, Starita-Fajardo G, Lucena López D, Iranzo Alcolea MP, et al. New Developments in the Treatment of IgG4-Related Disease: A Comprehensive Clinical Approach. J Clin Med 2025;14(19):6774 (literature searched through July 2025).

    Lire la source

  19. 19.Peyronel F, Della-Torre E, Maritati F, Urban ML, Bajema I, Schleinitz N, Vaglio A. IgG4-related disease and other fibro-inflammatory conditions. Nat Rev Rheumatol 2025;21(5):275-290.

    Lire la source

  20. 20.Stone JH. IgG4-related disease: lessons from the first 20 years. Rheumatology (Oxford) 2025;64(Suppl 1):i24-i27.

    Lire la source

  21. 21.Arias-Intriago M, Gomolin T, Jaramillo F, et al. IgG4-Related Disease: Current and Future Insights into Pathological Diagnosis. Int J Mol Sci 2025;26(11):5325.

    Lire la source

  22. 22.Khurram SA, Gueiros LAM, Soares CD, Fonseca FP. IgG4-Related Disease. In: Lymphoproliferative and Granulomatous Disorders of the Oral Cavity. Springer, 2025:207-213.

    Lire la source

  23. 23.Hao Q, Lian D, Zhou M, et al. Identification of candidate biomarkers for diagnosis, disease activity, and relapse prediction in IgG4-related disease. Arthritis Res Ther 2026;28(1):96

    Lire la source

  24. 24.Della-Torre E, Baker MC, Zhang W, et al; INDIGO Trial Investigators. Obexelimab for the Treatment of IgG4-Related Disease. N Engl J Med, published online 2 June 2026.

    Lire la source

  25. 25.Stone JH, Carruthers M, Baker MC, et al. A phase 2 trial of rilzabrutinib in IgG4-related disease. Annals of the Rheumatic Diseases, 2026.

    Lire la source

  26. 26.Duru N, van der Goes MC, Jacobs JWG, et al. EULAR evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis 2013;72(12):1905-1913.

    Lire la source

  27. 27.Beuschlein F, Else T, Bancos I, et al. European Society of Endocrinology and Endocrine Society Joint Clinical Guideline: Diagnosis and Therapy of Glucocorticoid-induced Adrenal Insufficiency. J Clin Endocrinol Metab 2024;109(7):1657-1683

    Lire la source

  28. 28.Fong AC, Cheung NW. The high incidence of steroid-induced hyperglycaemia in hospital. Diabetes Res Clin Pract 2013;99(3):277-280

    Lire la source

  29. 29.Nuthalapati M, Menon AR, Rajendran R, et al. IgG4-Related Disease in Urological Practice: A Case Series of Mistaken Malignancies. Indian J Surg Oncol 2025;16(6):1446-1451.

    Lire la source

  30. 30.Tomkins M, Martin-Grace J, Kennedy C, et al. Adrenal insufficiency is common amongst kidney transplant recipients receiving maintenance prednisolone and can be predicted using morning cortisol. Nephrol Dial Transplant 2023;38(1):236-245

    Lire la source

  31. 31.Mahajan A, Tinianow A, Katz G. IgG4-Related disease: From diagnosis to remission. Best Practice & Research Clinical Rheumatology 2025;39:102108.

    Lire la source

  32. 32.Peng L, Nie Y, Zhou J, et al. Withdrawal of immunosuppressants and low-dose steroids in patients with stable IgG4-RD (WInS IgG4-RD): an investigator-initiated, multicentre, open-label, randomised controlled trial. Ann Rheum Dis 2024;83(5):651-660

    Lire la source

  33. 33.2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases, European Alliance of Associations for Rheumatology

    Lire la source

  34. 34.Choosing Wisely Canada, Allergy and Clinical Immunology recommendations, Canadian Society of Allergy and Clinical Immunology, updated May 2025

    Lire la source

  35. 35.Yang F, Wang T, Liu Y. Risk factors for relapse of IgG4-related disease: a systematic review and meta-analysis. Clin Rheumatol 2025;44:4137-4147

    Lire la source

  36. 36.Angarola E, Pasqua A, Castro HM, Cáceres A, Spina JC, Casciato P. Clinical characteristics, disease course, and chronic organ damage in a real-world cohort of IgG4-related disease: insights from an Interdisciplinary Unit. Medicina Clínica 2026;166:107317

    Lire la source

  37. 37.Peyronel F, Palmisano A, Maritati F, et al. Methotrexate and low-dose prednisone in idiopathic retroperitoneal fibrosis: a randomised clinical trial. J Autoimmun 2025;157:103487

    Lire la source

  38. 38.Koster MJ, Ghaffar U, Duong SQ, et al. Incidence, prevalence and mortality of chronic periaortitis: a population-based study. Clin Exp Rheumatol 2022;40:751-757

    Lire la source

  39. 39.Dattani R, Barwick TD, El Wardany G, et al; RaDaR Rare Disease Group. An international patient-centred study of retroperitoneal fibrosis. QJM 2022;115(3):148-154

    Lire la source

  40. 40.Tang H, Yang H, Zhang P, et al. Malignancy and IgG4-related disease: the incidence, related factors and prognosis from a prospective cohort study in China. Sci Rep 2020;10:4910

    Lire la source

  41. 41.So H, Choi SJ, Park S, et al. Increased cancer risk in patients with IgG4-related disease in a nationwide South Korean cohort, 2012-2021. Sci Rep 2025;15:37273

    Lire la source

  42. 42.American College of Rheumatology. IgG4-Related Disease (IgG4-RD). Patient information page, updated February 2025.

    Lire la source

  43. 43.Gwozdz-Broczkowska A. Fatigue beyond inflammation in inflammatory rheumatic diseases: a narrative review and treatable-traits framework. Rheumatol Int 2026;46(8):232.

    Lire la source

  44. 44.US Food and Drug Administration. RAYOS (prednisone) delayed-release tablets, prescribing information, revision 12/2019.

    Lire la source

  45. 45.Liu Q, Zheng Y, Sturmlechner I, et al. IKZF1 and UBR4 gene variants drive autoimmunity and Th2 polarization in IgG4-related disease. J Clin Invest 2024;134(16):e178692.

    Lire la source

  46. 46.FAI2R. Maladie associee aux IgG4: les reponses a vos questions.

    Lire la source

  47. 47.Russell MD, Dey M, Flint J, et al. British Society for Rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatology (Oxford) 2023;62(4):e48-e88.

    Lire la source

  48. 48.European Medicines Agency. MabThera (rituximab), Summary of Product Characteristics.

    Lire la source

  49. 49.European Medicines Agency. Nordimet (methotrexate), Summary of Product Characteristics.

    Lire la source

  50. 50.US Food and Drug Administration. IMURAN (azathioprine) 50-mg scored tablets, product information, revision 12/2018.

    Lire la source

  51. 51.Yu K, Gao H, Liu S, et al. Perception of recurrence risk in patients with IgG4-related disease: a descriptive phenomenological study. Rheumatol Adv Pract 2025;9(1):rkae148.

    Lire la source

  52. 52.Newman JH, Shaver A, Sheehan JH, et al; Undiagnosed Disease Network. IgG4-related disease: Association with a rare gene variant expressed in cytotoxic T cells. Mol Genet Genomic Med 2019;7(6):e686.

    Lire la source

  53. 53.Karamya ZA, Kovacs A, Illes D, Czako B, Fazekas A, Farkas N, Hegyi P, Czako L. Prevalence of autoimmune pancreatitis in pancreatic resection for suspected malignancy: a systematic review and meta-analysis. BMC Gastroenterol 2024;24:278.

    Lire la source

  54. 54.Dures E, Farisogullari B, Santos EJF, et al. 2023 EULAR recommendations for the management of fatigue in people with inflammatory rheumatic and musculoskeletal diseases. Ann Rheum Dis 2024;83(10):1260-1267.

    Lire la source

  55. 55.Motor J, Gajewska A, Cienkowski K, et al. IgG4-related disease: focus on digestive system involvement. Front Immunol 2025;16:1584107.

    Lire la source

  56. 56.Orphanet. Enfermedad sistemica relacionada con IgG4 (ORPHA:596448), Spanish version.

    Lire la source

  57. 57.Orphanet. IgG4-gerelateerde systemische ziekte (ORPHA:596448), Dutch version.

    Lire la source

  58. 58.Orphanet. Maladie systemique liee a la presence d'anticorps IgG4 (ORPHA:596448), French version.

    Lire la source

  59. 59.Orphanet. IgG4-related systemic disease (ORPHA:596448), German version.

    Lire la source

  60. 60.European Medicines Agency. Uplizna (inebilizumab), European public assessment report.

    Lire la source

  61. 61.Erasmus MC. IgG4-gerelateerde ziekte, patient information.

    Lire la source

  62. 62.Carruthers MN, Topazian MD, Khosroshahi A, Witzig TE, Wallace ZS, Hart PA, Deshpande V, Smyrk TC, Chari S, Stone JH. Rituximab for IgG4-related disease: a prospective, open-label trial. Ann Rheum Dis 2015;74(6):1171-1177.

    Lire la source

  63. 63.Ebbo M, Grados A, Samson M, et al. Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients. PLoS One 2017;12(9):e0183844.

    Lire la source

  64. 64.ClinicalTrials.gov registry record NCT04520451. An Open Label, Two-Arm Study to Evaluate the Effect of Rilzabrutinib (PRN1008/SAR444671) on Safety and Disease Activity in Participants With IgG4-Related Disease. Phase 2, completed. Sponsor: Principia Biopharma, a Sanofi Company.

    Lire la source

  65. 65.ClinicalTrials.gov registry record NCT07190196. A Randomized, Phase 3, Double-blind, 52-week Study to Evaluate the Efficacy and Safety of Rilzabrutinib (SAR444671) Compared to Placebo in Adult Participants With Active IgG4-related Disease (RILIEF). Recruiting. Sponsor: Sanofi.

    Lire la source

  66. 66.Stapel SO, Asero R, Ballmer-Weber BK, Knol EF, Strobel S, Vieths S, Kleine-Tebbe J; EAACI Task Force. Testing for IgG4 against foods is not recommended as a diagnostic tool: EAACI Task Force Report. Allergy 2008;63(7):793-796.

    Lire la source

  67. 67.Orphanet. IgG4-related systemic disease (ORPHA:596448).

    Lire la source

  68. 68.Agencia Espanola de Medicamentos y Productos Sanitarios (AEMPS). Ficha tecnica prednisona, CIMA.

    Lire la source

  69. 69.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4. Haute Autorite de Sante, with FAI2R and CERAINOM-IgG4, November 2025.

    Lire la source

  70. 70.Het Oogziekenhuis Rotterdam. IgG4-gerelateerde orbitale ziekte, patient information.

    Lire la source

  71. 71.Imperial College Healthcare NHS Trust. RPF and IgG4-RD (retroperitoneal fibrosis and immunoglobulin-4 related disease), specialist nephrology service.

    Lire la source

National clinical guidance

Les liens ci-dessous mènent hors de ce site, pour vous aider à chercher plus loin par vous-même. Nous ne les contrôlons pas et ne les recommandons pas, et nous ne gagnons rien à les mentionner. Contrairement à nos propres sources ci-dessus, ils ne sont pas vérifiés par nous quant à leur origine ou leur exactitude. Confirmez toujours l'essentiel avec votre spécialiste.

  1. 1.Protocole National de Diagnostic et de Soins (PNDS), Maladie associee aux IgG4, Haute Autorite de Sante, FAI2R and CERAINOM-IgG4, November 2025.

    Lire la source

Product information (regulatory)

Les liens ci-dessous mènent hors de ce site, pour vous aider à chercher plus loin par vous-même. Nous ne les contrôlons pas et ne les recommandons pas, et nous ne gagnons rien à les mentionner. Contrairement à nos propres sources ci-dessus, ils ne sont pas vérifiés par nous quant à leur origine ou leur exactitude. Confirmez toujours l'essentiel avec votre spécialiste.

  1. 1.Ficha técnica prednisona, Agencia Española de Medicamentos y Productos Sanitarios (AEMPS), CIMA

    Lire la source

Patient information from specialist centres

Les liens ci-dessous mènent hors de ce site, pour vous aider à chercher plus loin par vous-même. Nous ne les contrôlons pas et ne les recommandons pas, et nous ne gagnons rien à les mentionner. Contrairement à nos propres sources ci-dessus, ils ne sont pas vérifiés par nous quant à leur origine ou leur exactitude. Confirmez toujours l'essentiel avec votre spécialiste.

  1. 1.Het Oogziekenhuis Rotterdam, IgG4-Gerelateerde Orbitale Ziekte (IgG4-related orbital disease), patient information. Recognised Dutch expertise centre for rare orbital conditions.

    Lire la source

  2. 2.Imperial College Healthcare NHS Trust, RPF and IgG4-RD service: specialist multidisciplinary service for retroperitoneal fibrosis and IgG4-related disease.

    Lire la source

Sites web utiles

Les liens ci-dessous mènent hors de ce site, pour vous aider à chercher plus loin par vous-même. Nous ne les contrôlons pas et ne les recommandons pas, et nous ne gagnons rien à les mentionner. Contrairement à nos propres sources ci-dessus, ils ne sont pas vérifiés par nous quant à leur origine ou leur exactitude. Confirmez toujours l'essentiel avec votre spécialiste.

Cet assistant partage des informations sourcées et ne peut pas vous diagnostiquer ni remplacer votre médecin. En cas d'urgence, cherchez d'abord des soins urgents.

Logo du livre Balanced DivinityDes mêmes auteurs : Balanced Divinity